Interactions of ligands with active and inactive conformations of the dopamine D2 receptor.
The affinities of 19 pharmacologically diverse dopamine D2 receptor ligands were determined for the active and inactive conformations of cloned human dopamine D2 receptors expressed in Ltk cells. The agonist [3H]quinpirole was used to selectively label the guanine nucleotide-binding protein-coupled, active receptor conformation. The antagonist [3H]raclopride, in the presence of the non-hydrolysable GTP-analogue Gpp(NH)p and sodium ions and in the absence of magnesium ions, was used to label the free inactive receptor conformation. The intrinsic activities of the ligands were determined in a forskolin-stimulated cyclic AMP assay using the same cells. An excellent correlation was shown between the affinity ratios (KR/KRG) of the ligands for the two receptor conformations and their intrinsic activity (r=0.96). The ligands included eight structurally related and enantiopure 2-aminotetralin derivatives; the enantiomers of 5-hydroxy-2-(dipropylamino)tetralin, 5-methoxy-2-(dipropylamino)tetralin, 5-fluoro-2-(dipropylamino)tetralin and 2-(dipropylamino)tetralin. The (S)-enantiomers behaved as full agonists in the cyclic AMP assay and displayed a large KR/KRG ratio. The (R)-enantiomers were classified as partial agonists and had lower ratios. The structure-affinity relationships of these compounds at the active and the inactive receptor conformations were analysed separately, and used in conjunction with a homology based receptor model of the dopamine D2 receptor. This led to proposed binding modes for agonists, antagonists and partial agonists in the 2-aminotetralin series. The concepts used in this study should be of value in the design of ligands with predetermined affinity and intrinsic activity.
Malmberg
A
A
Department of Molecular Pharmacology, Preclinical R&D, Astra Arcus, Södertälje, Sweden.
Mohell
N
N
Backlund Höök
B
B
Johansson
A M
AM
Hacksell
U
U
Nordvall
G
G
D002478:Cells, Cultured; D003001:Cloning, Molecular; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000096:biosynthesis; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D011487:Protein Conformation; D019257:Quinpirole / Q000494:pharmacology; D020891:Raclopride; D017448:Receptors, Dopamine D2 / Q000737:chemistry / Q000187:drug effects*; D012457:Salicylamides / Q000494:pharmacology; D013329:Structure-Activity Relationship
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D008024:Ligands; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D005576:Colforsin; D019257:Quinpirole; D020891:Raclopride; D000242:Cyclic AMP